Clene's Neurogenerative Candidate Shows Potential For Improved Long-Term Survival
Portfolio Pulse from Vandana Singh
Clene Inc. (NASDAQ:CLNN) has released long-term follow-up data for patients treated with CNM-Au8 30mg in the HEALEY ALS Platform Trial, showing significantly improved survival and a 49% decreased risk of death. In a pooled analysis of the HEALEY ALS Platform Trial and the RESCUE-ALS Trial, participants demonstrated a statistically significant 59% decreased risk of death compared to placebo patients. No serious adverse events have been related to CNM-Au8 treatment. The company's shares were up 0.22% at $0.46 on the last check Monday.
September 25, 2023 | 8:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clene Inc.'s long-term data for CNM-Au8 treatment shows improved survival rates and decreased risk of death for ALS patients. This positive news could potentially boost investor confidence and impact the company's stock positively.
The release of positive long-term data for Clene Inc.'s CNM-Au8 treatment shows potential for improved survival rates and decreased risk of death for ALS patients. This could potentially boost investor confidence in the company and its products, leading to increased demand for the company's stock and a potential increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100